Header Logo

Connection

Johnny Mahlangu to Injections, Subcutaneous

This is a "connection" page, showing publications Johnny Mahlangu has written about Injections, Subcutaneous.
Connection Strength

0,328
  1. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,157
  2. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
    View in: PubMed
    Score: 0,055
  3. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
    View in: PubMed
    Score: 0,046
  4. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,036
  5. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.